Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMMUNOCORE HOLDINGS PLC

(IMCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immunocore Announces Publication of Phase 3 Data Comparing tebentafusp with Investigator’s Choice in the New England Journal of Medicine

09/22/2021 | 06:00pm EST

Immunocore Holdings Plc announced that data from a phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator’s choice in first-line metastatic uveal melanoma (mUM) has been published in The New England Journal of Medicine (NEJM). Results from the randomized, open-label, phase 3 trial of tebentafusp vs. investigator’s choice in previously untreated HLA-A*02:01-positive patients with mUM demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment in mUM. The OS Hazard Ratio (HR) in the intent-to-treat population favored tebentafusp, HR=0.51 (95% CI: 0.37, 0.71); p


© S&P Capital IQ 2021
All news about IMMUNOCORE HOLDINGS PLC
11/11Immunocore to present at the Jefferies London Healthcare Conference
GL
11/10Immunocore Posts Narrower Q3 Loss, Lower Revenue
MT
11/10INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K
PU
11/10Corporate Presentation - November 2021
PU
11/10Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
GL
11/10Immunocore Holdings plc Reports Earnings Results for the Third Quarter and Nine Months ..
CI
11/09Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and ..
AQ
11/09Immunocore Holdings plc Presents New Data on Tebentafusp in Metastatic Cutaneous Melano..
CI
10/18IMMUNOCORE : to Collaborate With Medison Pharma to Expand Reach of Metastatic Uveal Melano..
MT
10/18IMMUNOCORE : and Medison Pharma Partner for Future Commercialization of Tebentafusp in Can..
GL
More news
Analyst Recommendations on IMMUNOCORE HOLDINGS PLC
More recommendations
Financials
Sales 2021 26,5 M 35,3 M 35,3 M
Net income 2021 -126 M -168 M -168 M
Net cash 2021 163 M 218 M 218 M
P/E ratio 2021 -9,21x
Yield 2021 -
Capitalization 1 196 M 1 595 M 1 597 M
EV / Sales 2021 39,0x
EV / Sales 2022 34,1x
Nbr of Employees 291
Free-Float 73,4%
Chart IMMUNOCORE HOLDINGS PLC
Duration : Period :
Immunocore Holdings plc Technical Analysis Chart | IMCR | US45258D1054 | MarketScreener
Technical analysis trends IMMUNOCORE HOLDINGS PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2 729,04 GBX
Average target price 3 900,45 GBX
Spread / Average Target 42,9%
EPS Revisions
Managers and Directors
Bahija Jallal Chief Executive Officer & Director
Brian R. DiDonato Chief Financial Officer & Head-Strategy
David Berman Head-Research & Development
Roy Steven Herbst Non-Executive Director
John Irving Bell Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOCORE HOLDINGS PLC0.00%1 595
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431